Clinical trials: Glucose Control
- Condition Glucose Control
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Postprandial Glycemic Response
A Study to Investigate the Effect of SFF on Glucose and Insulin Responses
This goal of this clinical study is to investigate the postprandial glycemic and insulinemic response in healthy adults after the consumption of: 1. Sugars from Fiber in comparison with dextrose 2.
- Trial name
- NCT05587426
- Testing
- SFF, Glucose, SFF chocolate chips
- Where
- Canada
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Cambridge Glycoscience
Obesity, Intra-Abdominal Fat
Effect of a Probiotic on Visceral Fat Accumulation
The study's main objective is to investigate if an extract containing the probiotic Bifidobacterium animalis subsp. lactis BPL1 (CECT 8145) has a positive effect on the accumulation of abdominal visceral fat in people with…
- Conditions
- Obesity, Intra-Abdominal Fat, Subcutaneous Fat, Abdominal
- Trial name
- BIFFAT (NCT02921217)
- Testing
- Active Probiotic, Inactivated probiotic, Control
- Where
- Spain
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- Biopolis S.L.
Diabetes
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single-dose GZR4
This trial is conducted in China. The aim of this trial is to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of single-dose GZR4.
- Trial name
- NCT06548815
- Testing
- GZR4
- Where
- China
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Gan and Lee Pharmaceuticals, USA
Diabetes Mellitus, Type 2
A Research Study Looking Into the Effect of Semaglutide and NNC0480 0389 on Blood Levels of a Birth Control Pill in Woman After Menopause
Novo Nordisk is developing a combination therapy with the investigational drug NNC0480-0389 and an already approved medicine called "semaglutide" for the treatment of type-2 diabetes (T2D).
- Trial name
- NCT05153564
- Testing
- Semaglutide 1.34 mg/mL, Semaglutide 3.0 mg/mL, NNC0480-0389 10 mg/mL
- Where
- Germany
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes Type 2
A Study to Evaluate the Safety and Effectiveness of DM199 in Healthy Subjects and Type 2 Diabetes Patients
DM199 (recombinant human tissue kallikrein-1) is a new investigational compound that may eventually be used for the treatment of Diabetes Mellitus Type 2. This is the first time that this compound is being given to humans.
- Trial name
- NCT01845064
- Testing
- DM199
- Where
- Netherlands
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- DiaMedica Therapeutics Inc
Healthy Subjects, Pharmacokinetics of ASP8232
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of ASP8232 in Subjects With Renal Impairment and in Type 2 Diabetes Mellitus Subjects With Chronic Kidney Disease
This study consists of two parts. Part 1 evaluates the effect of renal impairment on the PK and PD of a single dose of ASP8232. In addition, the safety and tolerability will be assessed.
- Conditions
- Healthy Subjects, Pharmacokinetics of ASP8232, Pharmacodynamics of ASP8232, Chronic Kidney Disease (CKD)
- Trial name
- NCT02218099
- Testing
- ASP8232
- Where
- 3 sites in Bulgaria, Moldova and 1 more
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
Postprandial Blood Glucose
Effect of an Arabinogalactan Product
Dietary fiber is an important nutrient that supports gastrointestinal function as well as blood glucose and cholesterol maintenance.
- Trial name
- NCT04005924
- Testing
- arabinogalactan
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Biofortis, Merieux NutriSciences
Glucose Metabolism Disorders
Effects of Deepure(Pu-erh Tea Extract) on Glycemic Control
This is a randomized, controlled, cross-over study on the effects of consumption of Deepure puerh tea extract (PTE) on glucose tolerance and metabolic markers.
- Trial name
- NCT03613688
- Testing
- Deepure
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Tasly Pharmaceuticals, Inc.
Focus of the Study is on Gut Health
Effects of a Dietary Fiber on Fecal Microbiota and Metabolism
The purpose of the study is to examine how a dietary fiber affects metabolism in healthy overweight and obese adults. The fiber will be added to foods that participants will consume for two, three-week periods.
- Trial name
- NCT01518088
- Testing
- Dietary Fiber
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Ingredion Incorporated
Type 2 Diabetes
Pharmacokinetic Similarity, Safety, and Immunogenicity of Semaglutide Injection and Ozempic ® Injection in Healthy Subjects.
This study is a randomized, open-label, single-dose, parallel-controlled biosimilar comparison study comparing the pharmacokinetics, safety and immunogenicity of the investigational drug and the active comparator in healthy adult…
- Trial name
- NCT06634927
- Testing
- Ozempic®, HDG1901
- Where
- China
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Type II Diabetes
Safety, Pharmacokinetics, and Food Effect of PS1 in Subjects
This is a phase I, double-blind, placebo-controlled, randomized, single- and multiple-ascending dose study to evaluate new study intervention, PS1.
- Trial name
- NCT05176210
- Testing
- PS1
- Where
- Taiwan
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Pharmasaga Co. Ltd.
Type 2 Diabetes
IDG-16177 for the Evaluation of Its Safety and Pharmacokinetics
This is a Phase I, first-in-human, randomised, double-blinded, placebo-and active-controlled study to assess the safety, tolerability, PK, PD, efficacy, and food-effect of IDG-16177 in healthy male subjects and patients with T2DM…
- Trial name
- NCT04982705
- Testing
- [Part 1.1] IDG-16177, [Part 2] Sitagliptin, [Part1.2] IDG-16177
- Where
- Germany
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- IlDong Pharmaceutical Co Ltd
Type 2 Diabetes Mellitus
FTIH of ECC5004 in Healthy and Diabetic Participants
This is a Phase 1, randomized, double-blind, placebo-controlled, single ascending dose and multiple ascending dose study of ECC5004 in healthy participants and in patients with Type 2 Diabetes Mellitus
- Trial name
- NCT05654831
- Testing
- ECC5004
- Where
- United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Eccogene
Type 2 Diabetes Mellitus
A Clinical Study to Investigate the Effect of SAR425899 on Energy Expenditure in Obese Subjects
Primary Objective: To assess in overweight to obese subjects the change in sleep energy expenditure after repeated subcutaneous (SC) doses of SAR425899.
- Trial name
- NCT03376802
- Testing
- SAR425899
- Where
- 2 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Sanofi
Obesity & Overweight, Circadian Rhythm Disorders
Effects of Akkermansia Muciniphila and Berberine Supplementation on Insulin Sensitivity in Night-shift Workers
Night shift work is associated with an increased risk of obesity, insulin resistance, and cardiometabolic disorders, largely due to circadian misalignment, disrupted sleep, and altered eating patterns.
- Conditions
- Obesity & Overweight, Circadian Rhythm Disorders, Gut Microbiota Modulation, Prediabetes (Insulin Resistance, Impaired Glucose Tolerance)
- Trial name
- Shift2Health (NCT07440147)
- Testing
- Verum (A)
- Where
- Austria
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- FH Joanneum Gesellschaft mbH
Diabetes Mellitus, Type 2
A Trial Evaluating AMG 127 in Healthy Participants and Participants With Type 2 Diabetes Mellitus
The main objective of this trial is to assess the safety and tolerability of AMG 127 as single dose and multiple doses in healthy participants and participants with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT07590193
- Testing
- AMG 127
- Where
- 2 sites in United States
- Volunteers
- 162 people, healthy volunteers welcome
- Sponsor
- Amgen
Diabetes Mellitus, Type 2, Healthy Males
A First in Human, Single Dose, Safety and Tolerability Study of MKC253 Inhalation Powder in Healthy Adult Males
26 subjects will be enrolled into 5 different dose groups. The trial will consist of a screening, a dosing and a follow-up visit.
- Trial name
- NCT00475371
- Testing
- MKC253 Inhalation Powder
- Where
- Netherlands
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Mannkind Corporation
Diabetes, Diabetes Mellitus, Type 2
Safety and Tolerability of Liraglutide in Healthy Volunteers and Subjects With Type 2 Diabetes
This trial is conducted in Europe. The aim of this trial is to assess the safety and tolerability (maximum tolerated dose) after single and multiple doses of NNC 90-1170 (liraglutide) in healthy volunteers and in subjects with…
- Conditions
- Diabetes, Diabetes Mellitus, Type 2, Healthy
- Trial name
- NCT01507285
- Testing
- liraglutide
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Safety, Tolerability and PK of Imeglimin in Japanese Volunteers
This study will assess the pharmacokinetics of single and repeated doses of imeglimin in healthy Japanese subjects, and the safety and tolerability of single and repeated doses of imeglimin in healthy Japanese subjects.
- Trial name
- NCT02373150
- Testing
- Imeglimin
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Poxel SA
Diabetes, Healthy
Comparing Semaglutide Administered Subcutaneously Once Daily to Semaglutide Administered Subcutaneously Once Weekly
This trial is conducted in Europe. The aim of this trial is to compare the steady-state exposure of semaglutide administered subcutaneously once daily to semaglutide administered subcutaneously once weekly in healthy subjects.
- Trial name
- NCT02557620
- Testing
- semaglutide
- Where
- Germany
- Volunteers
- 113 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S